Down-titration of omalizumab in a patient with chronic spontaneous urticaria.
Background: Omalizumab was demonstrated to be effective in patients with chronic urticaria resistant to antihistamines and is recommended as an add-on, third line treatment for such subjects. Patient and results: This article reports the history of a patient affected by chronic spontaneous urticaria, unresponsive to antihistamines, who received omalizumab, according to a personalized schedule. Prolonged administration of low dosage drug provided a good and long-lasting control of symptoms. Conclusion: This experience suggests that omalizumab could be used at low dose, with personalized plans, to reduce the risk of adverse events and costs of treatment.